Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease
- PMID: 30483546
- PMCID: PMC6207043
- DOI: 10.1002/jgh3.12019
Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease
Abstract
Background and aim: Many studies have found a relationship between hepatic iron, serum ferritin, and non-alcoholic fatty liver disease (NAFLD) or its progress. The aim of this study is to assess the value of serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis in NAFLD.
Methods: This study included 113 subjects who were classified into three groups. Group I included 30 healthy subjects as control with no clinical, radiological, and histological features of NAFLD. Group II included 31 NAFLD patients without hepatic fibrosis. Group III included 52 patients with hepatic fibrosis on top of NAFLD.
Results: Serum ferritin was determined using ferritin ELISA kit. Fibrosis 4 score was calculated. Liver biopsy was conducted for included patients. Significantly higher levels of serum ferritin were found in patients with hepatic fibrosis on top of NAFLD than controls. Receiver operating characteristic curve analysis revealed that an optimum cutoff level of 51.95 ng/mL was the best to predict fibrosis on top of NAFLD with diagnostic sensitivity and specificity of 65% and 60%, respectively, and area under the curve = 0.658.
Conclusion: Higher serum ferritin was found in patients with hepatic fibrosis on top of NAFLD. Serum ferritin was found to be a predictor of fibrosis on top of NAFLD with moderate sensitivity and specificity.
Keywords: ferritin; fibrosis; non‐alcoholic fatty liver disease.
Figures


Similar articles
-
Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review.Front Med (Lausanne). 2022 Aug 3;9:934989. doi: 10.3389/fmed.2022.934989. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35991666 Free PMC article.
-
Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution.Hepatol Res. 2014 Dec;44(14):E499-502. doi: 10.1111/hepr.12327. Epub 2014 Apr 10. Hepatol Res. 2014. PMID: 24628717
-
Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.Indian J Gastroenterol. 2015 May;34(3):200-8. doi: 10.1007/s12664-015-0572-5. Epub 2015 Jun 25. Indian J Gastroenterol. 2015. PMID: 26108652
-
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.J Clin Exp Hepatol. 2012 Jun;2(2):145-55. doi: 10.1016/S0973-6883(12)60103-0. Epub 2012 Jul 21. J Clin Exp Hepatol. 2012. PMID: 25755423 Free PMC article.
-
Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.Hepatol Res. 2016 Aug;46(9):862-70. doi: 10.1111/hepr.12647. Epub 2016 Feb 16. Hepatol Res. 2016. PMID: 26763834 Review.
Cited by
-
Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review.Front Med (Lausanne). 2022 Aug 3;9:934989. doi: 10.3389/fmed.2022.934989. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35991666 Free PMC article.
-
Genetic effects of iron levels on liver injury and risk of liver diseases: A two-sample Mendelian randomization analysis.Front Nutr. 2022 Sep 16;9:964163. doi: 10.3389/fnut.2022.964163. eCollection 2022. Front Nutr. 2022. PMID: 36185655 Free PMC article.
-
Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study.Nutrients. 2019 Oct 3;11(10):2359. doi: 10.3390/nu11102359. Nutrients. 2019. PMID: 31623368 Free PMC article.
-
Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease.J Genet Eng Biotechnol. 2023 Feb 9;21(1):13. doi: 10.1186/s43141-023-00467-z. J Genet Eng Biotechnol. 2023. PMID: 36757530 Free PMC article.
-
SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2022 Mar 27;23(7):3668. doi: 10.3390/ijms23073668. Int J Mol Sci. 2022. PMID: 35409028 Free PMC article. Review.
References
-
- Ratziu V, Bellentani S, Cortez‐Pinto HDC, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010; 53: 372–84. - PubMed
-
- Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005; 288: E462–8. - PubMed
-
- Bugianesi E, Leone N, Vanni E et al Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123: 134–40. - PubMed
-
- Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 2008; 28: 386–95. - PubMed
-
- Angulo P, Lindor KD. Non‐alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2002; 17: 186–90. - PubMed
LinkOut - more resources
Full Text Sources